We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




ANGPTL8 Levels Associated with Hyperlipidemia in Primary Nephrotic Syndrome

By LabMedica International staff writers
Posted on 28 Apr 2021
The typical clinical manifestations of Primary Nephrotic Syndrome (PNS) include massive proteinuria, hypoproteinemia, edema and/or hyperlipidemia. More...
Of these, marked proteinuria is the core clinical manifestation, and its severity often parallels the degree of hyperlipidemia.

Members of the angiopoietin-like protein (ANGPTL) family are mainly involved in vascular endothelial genesis and the regulation of lipid metabolism. Recent studies have detected ANGPTL8 in human and mouse serum, and moderate levels have been found in human urine. Studies have confirmed that ANGPTL8, ANGPTL4, and ANGPTL3 synergistically interact to participate in fatty acid transfer.

Nephrologists at the Guangzhou Women and Children's Medical Center (Guangzhou City, China) and their associates recruited 193 subjects including 133 patients with PNS and 60 healthy controls (HCs). The levels of serum cholesterol (CHOL), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), LDL-C, albumin (ALB), creatinine (CREA), urea (Ur) were measured by ARCHITECT c1600 automated biochemical analyzer (Abbott, Abbott Park, IL, USA). 24-hour urine total protein (24 hUTP), urine creatinine (UCr) were measured by the UniCel DxI 800 automated chemiluminescence immunoanalyzer (Beckman Coulter, Brea, CA, USA), and urine protein was measured by FUS-2000 automated urine analyzer (DIRUI, Changchun, China). The serum and urine ANGPTL8 concentrations were measured with ELISA kits.

The team reported that compared with healthy controls, subjects with primary nephrotic syndrome had higher levels of serum and urine ANGPTL8. In primary nephrotic syndrome patients, serum ANGPTL8 was positively correlated with cholesterol and triglycerides, while there was no correlation with 24 hour UTP. Urine ANGPTL8 was positively correlated with high-density lipoprotein cholesterol (and was significantly negatively correlated with creatinine, eGFR and 24 hour UTP. The urine ANGPTL8 concentrations in membranous nephropathy and mesangial proliferative glomerulonephritis pathological types were different.

The authors concluded that serum and urine ANGPTL8 levels in primary nephrotic syndrome patients were correlated with blood lipid levels and proteinuria, respectively, suggesting that ANGPTL8 may play a role in the development of primary nephrotic syndrome hyperlipidemia and proteinuria. The study was published on April 14, 2021 in the journal BMC Nephrology.

Related Links:
Guangzhou Women and Children's Medical Center
Abbott
Beckman Coulter
DIRUI



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.